PRLog (Press Release) - Feb. 12, 2013 - MONMOUTH JUNCTION, NJ.– Inventors Iwakura Yoichiro, Kakuta Shigeru and Suzuki, Shunsuke and assignee The University of Tokyo published United States Patent Application 20130011413 titled, Method and Pharmaceutical Composition for Treatment of Intestinal Disease. The patient details a method for using interleukin-related substances like an IL-17F inhibitor typified by an anti-IL-17F antibody to treat intestinal disease such as colon polyps or colorectal cancer. The patent cites Cleanascite™ from Biotech Support Group in a method for the selection of neutralizing antibodies to mouse IL-17F and IL-17A.
Neutralizing antibodies anti-IL-17F antibody and anti-IL-17A antibodies selected were cultured in serum-free medium and from the supernatant purified antibody was developed. The hybridoma culture supernatant was recovered periodically and a one fourth quantity of Cleanascite (registered trademark) (Biotech Support Group, LLC) was added to the recovered culture supernatant. Next at room temperature the samples were shaked for 10 minutes followed by centrifugation at 2000rpm to recover the supernatant. Subsequently, filtering, purification, elution, dialysis, filter sterilizing was followed on the samples and protein concentration and the degree of purification was confirmed.
For detailed protocols of the published article click
http://www.freepatentsonline.com/y2013/0011413.html
Characteristics Of Cleanascite™ Lipid Removal Reagent and Clarification
A high binding capacity for lipids with minimal cross-reactivity with proteins
Effectively replaces chlorinated/fluorinated hydrocarbons (eg. freon) and it is environmentally friendly.
Helps purify antibodies, recombinant proteins, nucleic acids, proteoglycans
Ideal for clarifying ascites, serum, cell & tissue culture, bile and organ homogenates
Clarifies saliva and fecal components
Very low protein binding
Does not bind to DNA, RNA, enzymes and proteins
Leaves glycoproteins, antibodies, nucleic acids, hemoglobin, proteoglycans, nucleic acids, serum components(such as hormones, nutrients, globulins, clotting factors, transport proteins) alone
Extends the life of membrane and chromatographic columns.
Enrichment of delipidated tissue samples
Ideal for delipidation treatments for downstream processing of large-scale therapeutic proteins, enzymes and monclonal antibodies.
Cleanascite™ selectively removes lipids, cell debris, lipoproteins, floating fats, impurities from cohn paste, transgenic milk, egg yolk and biological samples for pretreatment of samples prior to purification. The reagent is a solid-phase, non-ionic adsorbent supplied as a suspension in saline, ready for use. Simply add, centrifuge and/or filter. The clarified supernatant is ready for subsequent downstream processing or analysis.
For more information, visit:
Cleanascite™ Lipid Removal Reagent and Clarification
http://www.biotechsupportgroup.com/node/73
About Biotech Support Group LLC
Biotech Support Group LLC is a leading provider of genomics and proteomics sample preparation products and enrichment reagent kits as well as integrated biotechnology services for life sciences research, biomarker and drug discovery. Based in New Jersey, it’s principal products include: AlbuVoid™ for albumin depletion, Cleanascite™ for lipid adsorption and clarification, NuGel™ for passivated silica-based affinity chromatography, and ProCipitate™ & ProPrep™ for nucleic acid isolation. Currently, Biotech Support Group LLC and ProFACT Proteomics Inc., are collaborating on the development of a proteomics platform used in functional profiling for proteomic analysis and a separations method for generating sub-proteomes used in biomarker and functional proteomic prospecting. For more information, go to: www.biotechsupportgroup.com
CONTACT:
Dr.Swapan Roy
Biotech Support Group
1 Deer Park Drive, Suite M,
Monmouth Junction, NJ 08852, USA
732-274-2866
sales@biotechsupportgroup.com
Cleanascite™ References
Patents
Iwakura Yoichiro, Kakuta Shigeru, Suzuki, Shunsuke - United States Patent Application 20130011413. Method and Pharmaceutical Composition for Treatment of Intestinal Disease
Mcintyre, John A. United States Patent: 20120107841. Serum Diagnostic Method, Biomarker and Kit for Early Detection and Staging of Alzheimer’s Disease
Morre, James D et al. United States Patent: 20030170757. Monoclonal antibodies specific for neoplasia-specific NADH: disulfide reductase
DJ Morre, NM McCarty, D Morre et al United States Patent: 7053188. Monoclonal antibodies specific for neoplasia-specific NADH: disulfide reductase
David C. Jones. United States Patent: 7999084. Devices and methods for reducing matrix effects
J Krupey - United States Patent: 5885921 Hydrophobic silica adsorbents for lipids
Morre, James D et al. United States Patent: 20030170757. Monoclonal antibodies specific for neoplasia-specific NADH: disulfide reductase
Mcintyre, John A. United States Patent: 20120107841. Serum Diagnostic Method, Biomarker and Kit for Early Detection and Staging of Alzheimer’s Disease
